1. Rini, BI, Powles, T, Atkins, MB, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 2019; 393: 2404–2415.
Google Scholar | Crossref | Medline2. Rini, BI, Plimack, ER, Stus, V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. New Engl J Med 2019; 380: 1116–1127.
Google Scholar | Crossref | Medline3. Motzer, RJ, Tannir, NM, McDermott, DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. New Engl J Med 2018; 378: 1277–1290.
Google Scholar | Crossref | Medline4. Motzer, RJ, Penkov, K, Haanen, J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. New Engl J Med 2019; 380: 1103–1115.
Google Scholar | Crossref | Medline5. Motzer, R, Alekseev, B, Rha, SY, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. New Engl J Med 2021; 384: 1289–1300.
Google Scholar | Crossref | Medline6. Choueiri, TK, Powles, T, Burotto, M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. New Engl J Med 2021; 384: 829–841.
Google Scholar | Crossref | Medline7. Motzer, RJ, Rini, BI, McDermott, DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 2019; 20: 1370–1385.
Google Scholar | Crossref | Medline8. Albiges, L, Tannir, NM, Burotto, M, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open 2020; 5: e001079.
Google Scholar | Crossref | Medline9. Choueiri, TK, Motzer, RJ, Rini, BI, et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol 2020; 31: 1030–1039.
Google Scholar | Crossref | Medline10. Powles, T, Plimack, ER, Soulières, D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol 2020; 21: 1563–1573.
Google Scholar | Crossref | Medline11. Messina, C, Messina, M, Cattrini, C. From astrology to prostate cancer: what is the role of subgroup analyses? Ann Oncol 2020; 31: 437–438.
Google Scholar | Crossref | Medline12. Exelixis . Study of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced or metastatic renal cell carcinoma (COSMIC-313). Identification no. NCT03937219, 2019, https://clinicaltrials.gov/ct2/show/NCT03937219
Google Scholar13. Quhal, F, Mori, K, Bruchbacher, A, et al. First-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur Urol Oncol. Epub ahead of print 20 March 2021. DOI: 10.1016/j.euo.2021.03.001.
Google Scholar | Crossref